US3190802A - Shaving composition and method of using same - Google Patents

Shaving composition and method of using same Download PDF

Info

Publication number
US3190802A
US3190802A US227528A US22752862A US3190802A US 3190802 A US3190802 A US 3190802A US 227528 A US227528 A US 227528A US 22752862 A US22752862 A US 22752862A US 3190802 A US3190802 A US 3190802A
Authority
US
United States
Prior art keywords
shaving
pilomotor
compositions
shave
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US227528A
Inventor
Zeile Karl
Stahle Helmut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CH Boehringer Sohn AG and Co KG
Boehringer Ingelheim GmbH
Original Assignee
CH Boehringer Sohn AG and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CH Boehringer Sohn AG and Co KG filed Critical CH Boehringer Sohn AG and Co KG
Application granted granted Critical
Publication of US3190802A publication Critical patent/US3190802A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00—Preparations for removing hair or for aiding hair removal
    • A61Q9/02—Shaving preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Definitions

  • the present invention relates to shaving compositions, such as shaving soaps, shaving sticks, brush-type shaving creams, brushless shaving creams, aerosol shaving foams, pre-shave lotions and pre-shave creams, which are composed of the customary ingredients for such compositions and, in addition, contain a compound which is stable under acid as well as alkaline conditions and produces a temporary pilomotor effect upon the hairs ofthe facial beard.
  • shaving compositions such as shaving soaps, shaving sticks, brush-type shaving creams, brushless shaving creams, aerosol shaving foams, pre-shave lotions and pre-shave creams, which are composed of the customary ingredients for such compositions and, in addition, contain a compound which is stable under acid as well as alkaline conditions and produces a temporary pilomotor effect upon the hairs ofthe facial beard.
  • compositions comprising an ingredient which produces a pilomotor effect on the facial beard are well known.
  • the concept of such compositions has heretofore been capable of application exclusively to pre-shave lotions adapted for use prior to shaving with electric dry shavers.
  • the pilomotor action of such preshave lotions is caused by the fact that the arrectus pilorum (hair follicle muscle) is contracted upon contact with the lotion and remains contracted for a period of time sufficient to last through the shaving operation or a little longer. This contraction of the arrectus pilorum causes the air stubble to be pushed further above the skin surrace line by about 0.2-0.3 mm. so that the beard hair can be cut in this position by the electric razor.
  • blade razor shaving compositions such as shaving soaps or shaving creams of the brush or brushless type, which are alkaline in character, has met with failure because they decompose under the alkaline conditions existing in blade razor shaving compositions, forming decomposition products having no pilomotor effect whatsoever.
  • Another object of the present invention is to provide a stable ingredient having a pilomotor effect for shaving compositions, such as shaving soaps and creams of the brush or brushless type as well as electric pre-shave lotions and creams.
  • Z-(phenylamino)-l,3-diazacyciopentenes-(Z) of the formula wherein R and R are selected'from the group consisting of methyl, ethyl and chlorine, and their dermatologically acceptable, non-toxic acid addition salts produce excellent pilomotor effects and are stable under acid, neutral as well as alkaline conditions, and that the above objects and advantages may be achievedby incorporating compounds of the Formula I or their non-toxic acid addition salts into customary shaving compositions, such as shaving soaps and creams of the brush, brushless or aerosol foam type or electric pro-shave lotions and creams.
  • customary shaving compositions we mean electric pre-sl1ave and blade razor shaving compositions which are described in Cosmetics, Science and Technology, edited by Edward Sagarin, Interscience Publishers, Inc., New York (1957). However, it should be understood that our invention may be practiced in conjunction with any shaving composition, regardless of whether the composition is acid, neutral or alkaline in character.
  • the compounds of the Formula I or'their non-toxic acid addition salts are advantageously added to and blended into customary shaving compositions in amounts of 0.1 to 5% by weight based on the total 'weightof the shaving composition.
  • Shaving compositions thus modified with the Z-(phenylamino) 1,3-diazacyclopentenes-(2) of the Formula I or their non-toxic acid addition salts have the advantage .of being completely stable even over long periods of storage.
  • the 2-(phenylamino)'-1,3-diazacyclopentene- (2) component imparts to. such vcompositions pilomotor properties in addition to the other properties.
  • the pilomotor eifect of shaving compositions modified in accordance with the present invention is characterized by an extraordinarily rapid onset and satisfactory duration throughout the shaving operation. i
  • the 2- (phenylarnino)-1,3-diazacyclopentene-(2) compounds of the Formula I above and their non-toxic acid addition salts are novel compounds. They, as well as a method for their preparation, are described in our copending application, filed on even date, entitled Z-(Arylamino)-l,3-Diazacycloalkenes. a
  • aqueous alcoholic solutions presents no difliculty of any kind.
  • Soaps and creams are advantageously modified with a solutlon promoter, such as glycerin or other glycols.
  • Parts 2 (2',6' diethylphenyl) amino-1,3-diazacyclopentene-(2) hydrochloride 0.50 Aidpic acid di-isopropyl ester 10.00 Ethanol 60.00 Boric acid 1.00 Perfume 0.50 Distilled water 28.00
  • Parts 2 (2',6' dimethylphenyl)-amino-1,3-diazacyclopentene-(2) 0.20 1,3-butylene glycol 4.00 Stearic acid 52.00 Coconut oil 15.00 KOH 13.30 NaOH 0.50 Perfume 1.00 Distilled water 14.00
  • the alkaline wet-shave as well as the acidic pro-shave compositions illustrated above containing the compounds of the Formula I as the active pilomotor ingredient are stable over extended periods of time and exhibit excellent pilomotor effects.
  • the quantity of pilomotor ingredient in these compositions may be varied within the percentage limits set forth above to meet particular requirements.
  • the active pilomotor ingredient according to the present invention may be incorporated into other shaving compositions with equal success.
  • the particular compounds illustrated may be replaced by any of the other compounds embraced by Formula I above or their non-toic dermatologically acceptable acid addition salts. Examples of such acid addition salts are the hydrobromide, hydroiodide, sulfate, nitrate, suocinate, maleate, tartrate, citrate and the like.
  • a shaving soap having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of a compound selected from a group consisting of 2 (phenylamino) 1,3 -diazacyclopentenes (2) of the formula wherein R and R are selected from the group consisting of methyl, ethyl and chlorine, and their non-toxic, demratologically acceptable acid addition salts.
  • a shaving cream having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of a compound selected from the group consisting of 2 (phenylamino) 1,3 diazacyclopentenes (2) of the formula wherein R and R are selected from the group consisting of methyl, ethyl and chlorine, and their non-toxic, dermatologically acceptable acid addition salts.
  • a shaving cream having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of 2 (2',6-dichlorophenyl) amino-diazacyclopentene- (2).
  • a shaving soap having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of 2-(2',6'-dimethylplrenyl)-amino 1,3 diazacyclopentene- (2).
  • the method of producing a pilomotor effect which comprises applying to the skin a compound selected from the group consisting of 2-(phenylamino)-l,3-diazacyclopentenes-( 2) of the formula wherein R and R are selected from the group consisting of methyl, ethyl and chlorine, and their non-toxic, dermatologically acceptable acid addition salts.
  • the method of producing a pilomotor effect, which 5 comprises applying to the skin 2-(2',6'-diethy1phenyl)- amino-1,3-diazacyc1opentene-(2) hydrochloride.
  • the method of producing a pilomotor effect which comprises applying to the skin 2-(2',6'-dich1oropheny1)- amino 1,3-diazacyc1opentene-(2).
  • the method of producing a pilomotor efiect which comprises applying to the skin 2-(2,6-dimethy1pheny1)- amino-1,3-diazacyclopentene- (2) 9.
  • the method of producing a pilomonor effect, which 6 comprises applying to the skin 2-(2'-chloro-6'-methy1- phenyl -a1nino- 1,3-diazacyc1opentene- (2) hydrochloride.

Description

United States Patent 9 Claims. (a. 16785) This invention relates to shaving compositions and especially to improved shaving compositions adapted for use in conjunction with blade razors as well as electric razors.
More particularly, the present invention relates to shaving compositions, such as shaving soaps, shaving sticks, brush-type shaving creams, brushless shaving creams, aerosol shaving foams, pre-shave lotions and pre-shave creams, which are composed of the customary ingredients for such compositions and, in addition, contain a compound which is stable under acid as well as alkaline conditions and produces a temporary pilomotor effect upon the hairs ofthe facial beard.
Compositions comprising an ingredient which produces a pilomotor effect on the facial beard are well known. However, the concept of such compositions has heretofore been capable of application exclusively to pre-shave lotions adapted for use prior to shaving with electric dry shavers. The pilomotor action of such preshave lotions is caused by the fact that the arrectus pilorum (hair follicle muscle) is contracted upon contact with the lotion and remains contracted for a period of time sufficient to last through the shaving operation or a little longer. This contraction of the arrectus pilorum causes the air stubble to be pushed further above the skin surrace line by about 0.2-0.3 mm. so that the beard hair can be cut in this position by the electric razor. When the contracting effects of the lotion wear off after completion of the shaving operation and the tonus of the hair follicle muscle returns to normal, the cut beard hair retracts to a point substantially below the skin surface line, giving the eifect of what is commonly referred to as a close shave. There is the further, advantage that men with a heavy beard and rapid beard growth can maintain a presentable appearance for longer periods of time and need to shave only once a day instead of twice.
A number of compounds having a pilomotor effect have been pioposed and investigated (Arzneimittelforschung, 4 (1954), 63-66). However, the common disadvantage of those investigated compounds is that they are highly unstable under evenmildl-y alkalineconditions. Hence, their employment as pilomotoringredients has been necessarily confined to compositions which are acidic in character, notably to acidic pre-shave lotions adapted for use in conjunction with electric dry shavers. Any attempt to incorporate them into blade razor shaving compositions, such as shaving soaps or shaving creams of the brush or brushless type, which are alkaline in character, has met with failure because they decompose under the alkaline conditions existing in blade razor shaving compositions, forming decomposition products having no pilomotor effect whatsoever. i
It is, therefore, an. object ofthe present invention to provide stablelacid, neutral or alkaline shaving composiamassz Patented June 22, 1955 tions which produce not only the customary eifects upon the facial beard but also a pilomotor effect.
Another object of the present invention is to provide a stable ingredient having a pilomotor effect for shaving compositions, such as shaving soaps and creams of the brush or brushless type as well as electric pre-shave lotions and creams.
Other objects and advantages of the present invention will become apparent as the description thereof proceeds.
We have discovered that Z-(phenylamino)-l,3-diazacyciopentenes-(Z) of the formula wherein R and R are selected'from the group consisting of methyl, ethyl and chlorine, and their dermatologically acceptable, non-toxic acid addition salts produce excellent pilomotor effects and are stable under acid, neutral as well as alkaline conditions, and that the above objects and advantages may be achievedby incorporating compounds of the Formula I or their non-toxic acid addition salts into customary shaving compositions, such as shaving soaps and creams of the brush, brushless or aerosol foam type or electric pro-shave lotions and creams.
By customary shaving compositions we mean electric pre-sl1ave and blade razor shaving compositions which are described in Cosmetics, Science and Technology, edited by Edward Sagarin, Interscience Publishers, Inc., New York (1957). However, it should be understood that our invention may be practiced in conjunction with any shaving composition, regardless of whether the composition is acid, neutral or alkaline in character. The compounds of the Formula I or'their non-toxic acid addition salts are advantageously added to and blended into customary shaving compositions in amounts of 0.1 to 5% by weight based on the total 'weightof the shaving composition.
Shaving compositions thus modified with the Z-(phenylamino) 1,3-diazacyclopentenes-(2) of the Formula I or their non-toxic acid addition salts have the advantage .of being completely stable even over long periods of storage. Moreover, the 2-(phenylamino)'-1,3-diazacyclopentene- (2) component imparts to. such vcompositions pilomotor properties in addition to the other properties. The pilomotor eifect of shaving compositions modified in accordance with the present invention is characterized by an extraordinarily rapid onset and satisfactory duration throughout the shaving operation. i
The 2- (phenylarnino)-1,3-diazacyclopentene-(2) compounds of the Formula I above and their non-toxic acid addition salts are novel compounds. They, as well as a method for their preparation, are described in our copending application, filed on even date, entitled Z-(Arylamino)-l,3-Diazacycloalkenes. a
The' following examples shall further illustrate the present invention and enable others skilled in the art to understand it morecompletely. It should be understood, however, that our invention is not limited to these particular examples. The parts are parts by weight.
Since the active ingredients with pilomotor activity according to the present invention are readily soluble in water and alcohol, the preparation of aqueous alcoholic solutions presents no difliculty of any kind. Soaps and creams are advantageously modified with a solutlon promoter, such as glycerin or other glycols.
EXAMPLE I Pro-shave lotion The pre-shave lotion is compounded in the usual manner from the following ingredients:
Parts 2 (2',6' diethylphenyl) amino-1,3-diazacyclopentene-(2) hydrochloride 0.50 Aidpic acid di-isopropyl ester 10.00 Ethanol 60.00 Boric acid 1.00 Perfume 0.50 Distilled water 28.00
Total 100.00
EXAMPLE II Shaving soap in cream form The shaving soap cream is compounded in the usual manner from the following ingredients:
Parts 2 (2,6' dichlorophenyl) amino diazacyclopentene-(2) 0.30 Stearic acid 18.00 Coconut oil 12.00 Potassium hydroxide 7.00 Sodium hydroxide 1.00 Stearyl alcohol 0.70 Distilled Water 42.00
Total 100.00
EXAMPLE III Shaving soap The shaving soap is compounded in the usual manner from the following ingredients:
Parts 2 (2',6' dimethylphenyl)-amino-1,3-diazacyclopentene-(2) 0.20 1,3-butylene glycol 4.00 Stearic acid 52.00 Coconut oil 15.00 KOH 13.30 NaOH 0.50 Perfume 1.00 Distilled water 14.00
Total 100.00
EXAMPLE IV Pre-shave cream The pre-shave cream is compounded in the usual manner from the following ingredients:
The alkaline wet-shave as well as the acidic pro-shave compositions illustrated above containing the compounds of the Formula I as the active pilomotor ingredient are stable over extended periods of time and exhibit excellent pilomotor effects. Of course, the quantity of pilomotor ingredient in these compositions may be varied within the percentage limits set forth above to meet particular requirements. Moreover, the active pilomotor ingredient according to the present invention may be incorporated into other shaving compositions with equal success. Finally, the particular compounds illustrated may be replaced by any of the other compounds embraced by Formula I above or their non-toic dermatologically acceptable acid addition salts. Examples of such acid addition salts are the hydrobromide, hydroiodide, sulfate, nitrate, suocinate, maleate, tartrate, citrate and the like.
While We have illustrated our invention with the aid of certain specific embodiments thereof, it Will be readily apparent to others skilled in the art that our invention is not limited to these embodiments and that various changes and modificaions may be made Without departing from the spirit of the invention or the scope of the appended claims.
We claim:
1. A shaving soap having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of a compound selected from a group consisting of 2 (phenylamino) 1,3 -diazacyclopentenes (2) of the formula wherein R and R are selected from the group consisting of methyl, ethyl and chlorine, and their non-toxic, demratologically acceptable acid addition salts.
2. A shaving cream having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of a compound selected from the group consisting of 2 (phenylamino) 1,3 diazacyclopentenes (2) of the formula wherein R and R are selected from the group consisting of methyl, ethyl and chlorine, and their non-toxic, dermatologically acceptable acid addition salts.
3. A shaving cream having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of 2 (2',6-dichlorophenyl) amino-diazacyclopentene- (2).
4. A shaving soap having uniformly distributed therein from 0.1 to 5% by weight, based on the total weight, of 2-(2',6'-dimethylplrenyl)-amino 1,3 diazacyclopentene- (2).
5. The method of producing a pilomotor effect, which comprises applying to the skin a compound selected from the group consisting of 2-(phenylamino)-l,3-diazacyclopentenes-( 2) of the formula wherein R and R are selected from the group consisting of methyl, ethyl and chlorine, and their non-toxic, dermatologically acceptable acid addition salts.
6. The method of producing a pilomotor effect, which 5 comprises applying to the skin 2-(2',6'-diethy1phenyl)- amino-1,3-diazacyc1opentene-(2) hydrochloride.
7. The method of producing a pilomotor effect, which comprises applying to the skin 2-(2',6'-dich1oropheny1)- amino 1,3-diazacyc1opentene-(2).
8. The method of producing a pilomotor efiect, which comprises applying to the skin 2-(2,6-dimethy1pheny1)- amino-1,3-diazacyclopentene- (2) 9. The method of producing a pilomonor effect, which 6 comprises applying to the skin 2-(2'-chloro-6'-methy1- phenyl -a1nino- 1,3-diazacyc1opentene- (2) hydrochloride.
References Cited by the Examiner Najer: B111. Soc. Chem, France, No. 19 61, 2114-2126.
JULIAN S. LEVITT, Primary Examiner.
FRANK CACCIAPAGLIA, JR., Examiner.
atent No. 3,190,802 June 22, 1965 Karl Zeile et al.
It is hereby certified that ent requiring correction and the corrected below.
error appears in the above numbered patt the said Letters Patent should read as Column 4, lines 65 to 70, the formula should appear as shown below instead of as in the patent:
2 NHC\ 1| 1 CH 2 H EAL) Signed and sealed this 28th day of December 1965.
test:
NEST W. SWIDER EDWARD J. BRENNER testing Officer Commissioner of Patents

Claims (1)

1. A SHAVING SOAP HAVING UNIFORMLY DISTRIBUTED THEREIN FROM 0.1 TO 5% BY WEIGHT, BASES ON THE TOTAL WEIGHT, OF A COMPOUND SELECTED FROM A GROUP CONSISTING OF 2 - (PHENYLAMINO) - 1,3 - DIAZACYCLOPENTENES - (2) OF THE FORMULA
US227528A 1961-10-09 1962-10-01 Shaving composition and method of using same Expired - Lifetime US3190802A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEB0064319 1961-10-09

Publications (1)

Publication Number Publication Date
US3190802A true US3190802A (en) 1965-06-22

Family

ID=6974340

Family Applications (2)

Application Number Title Priority Date Filing Date
US227528A Expired - Lifetime US3190802A (en) 1961-10-09 1962-10-01 Shaving composition and method of using same
US227527A Expired - Lifetime US3202660A (en) 1961-10-09 1962-10-01 Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes

Family Applications After (1)

Application Number Title Priority Date Filing Date
US227527A Expired - Lifetime US3202660A (en) 1961-10-09 1962-10-01 Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes

Country Status (9)

Country Link
US (2) US3190802A (en)
CH (1) CH409980A (en)
CY (1) CY416A (en)
DK (2) DK107029C (en)
FI (1) FI42564C (en)
GB (1) GB1016514A (en)
MY (1) MY6700148A (en)
NL (2) NL6800891A (en)
SE (1) SE301024B (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462433A (en) * 1965-10-01 1969-08-19 Boehringer Sohn Ingelheim Derivatives of 2-(2'-halo-anilino)1,3-diazacyclo-pentene-(2)
US3959160A (en) * 1973-05-16 1976-05-25 Wilkinson Sword Limited Aerosol shaving foam compositions
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4262005A (en) * 1978-05-31 1981-04-14 The Boots Company Limited Compounds, compositions and methods for controlling pests
US4287201A (en) * 1980-03-03 1981-09-01 Merck & Co., Inc. Anovulatory method and chicken feed compositions
US4312879A (en) * 1980-08-14 1982-01-26 Richardson-Merrell Inc. Clonidine and lofexidine as antidiarrheal agents
US4450170A (en) * 1980-07-09 1984-05-22 Beecham Group Limited Treatment of diarrhoea with 2-aminoimidazoline derivatives
US4853216A (en) * 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US20030114425A1 (en) * 1995-04-20 2003-06-19 Boehringer Ingelheim Pharma Kg Compounds and methods for treating urinary incontinence
US20070277873A1 (en) * 2006-06-02 2007-12-06 Emcore Corporation Metamorphic layers in multijunction solar cells
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US20090263462A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods for Treating Conditions Such as Dystonia and Post-Stroke Spasticity with Clonidine
US20090264490A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US20090263448A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Clonidine Formulation in a Polyorthoester Carrier
US20090263461A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090263450A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US20090263441A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Drug depots having diffreent release profiles for reducing, preventing or treating pain and inflammation
US20090263454A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090263460A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US20090264491A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20090263459A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and compositions for treating intervertebral disc herniations
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US20090263463A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263321A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Compositions and Methods for Treating Post-Operative Pain Using Clonidine and Bupivacaine
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US20100137369A1 (en) * 2008-12-01 2010-06-03 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US20110014259A1 (en) * 2009-07-17 2011-01-20 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US20110027340A1 (en) * 2009-07-31 2011-02-03 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) * 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236857A (en) * 1961-10-09 1966-02-22 Boehringer Sohn Ingelheim 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
DE1670274A1 (en) * 1966-10-31 1970-07-16 Boehringer Sohn Ingelheim New process for the preparation of 2-arylamino-1,3-diazacycloalkenene (2)
BE755270A (en) * 1969-08-27 1971-02-25 Sandoz Sa NEW DERIVATIVES OF BENZO (CD) INDOLE, THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE DERIVATIVES
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
DE2404754A1 (en) * 1974-02-01 1975-08-14 Boehringer Sohn Ingelheim MEANS OF DECREASING HEART RATE
US4024259A (en) * 1976-01-26 1977-05-17 American Hoechst Corporation 3-Anilino-2,4-diazabicyclo[3.2.1]octenes
DE2636732A1 (en) * 1976-08-14 1978-02-16 Boehringer Sohn Ingelheim NEW SUBSTITUTED 2-PHENYLAMINO IMIDAZOLINE (2), THE ACID ADDITION SALTS THEREOF, THE MEDICINAL PRODUCTS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION THEREOF
NL7711390A (en) * 1977-10-18 1979-04-20 Philips Nv NEW 2-ARYLIMINO-HEXAHYDOPYRIMIDINES AND IMI-DAZOLIDINES, SALTS AND COMPLEXES THEREOF, METHOD FOR PREPARING THE NEW COMPOUNDS, AND FUNGICIDE PREPARATIONS BASED ON THE NEW COMPOUNDS.
DE2962626D1 (en) * 1978-08-16 1982-06-09 Farmos Oy 2,6-dichlorophenyl-substituted amino-imidazole derivatives, processes of preparing such derivatives and pharmaceutical preparations comprising said derivatives
GB2069481B (en) * 1980-02-13 1983-07-27 Farmos Oy Substituted imidazole derivatives
US4603141A (en) * 1984-11-30 1986-07-29 Giles Thomas D Oral clonidine treatment of congestive heart failure
AU585309B2 (en) * 1984-12-14 1989-06-15 Alcon Laboratories, Inc. Method for controlling ocular bleeding
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives
US5212196A (en) * 1986-10-21 1993-05-18 Alcon Laboratories, Inc. Control of post-surgical intraocular pressure using clonidine derivatives
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
DE3904795C2 (en) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmaceutical preparation and its use
EP0664707B1 (en) * 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
US5369128A (en) * 1993-06-21 1994-11-29 Iowa State University Research Foundation, Inc. Method of synchronizing farrowing in swine
US5663189A (en) * 1993-07-01 1997-09-02 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US6225305B1 (en) 1993-10-04 2001-05-01 Glaxo Wellcome Inc. Substituted urea and isothiorea derivatives as no synthase inhibitors
US6090846A (en) * 1994-06-01 2000-07-18 Glaxo Wellcome Inc. Substituted urea and isothiourea derivatives as no synthase inhibitors
US6297276B1 (en) 1993-10-04 2001-10-02 Glaxosmithkline Substituted urea and isothiourea derivatives as no synthase inhibitors
US5914342A (en) * 1995-06-07 1999-06-22 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5801188A (en) * 1997-01-08 1998-09-01 Medtronic Inc. Clonidine therapy enhancement
UA64751C2 (en) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Treatment of insulin tolerance using substances increasing growth hormone secretion
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
US20020169193A1 (en) * 2001-02-10 2002-11-14 Pascale Pouzet Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
DE10106214A1 (en) * 2001-02-10 2002-08-14 Boehringer Ingelheim Pharma New alkyl-phenylimino-imidazolidine derivatives for the treatment of urinary incontinence
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10163239A1 (en) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP1981498A2 (en) * 2006-01-27 2008-10-22 F. Hoffmann-la Roche AG Use of 2-imidazoles for the treatment of cns disorders
EP2076497B1 (en) 2006-10-19 2012-02-22 F. Hoffmann-La Roche AG Aminomethyl-4-imidazoles
JP5064511B2 (en) 2006-11-02 2012-10-31 エフ．ホフマン−ラ ロシュ アーゲー Substituted 2-imidazoles as trace amine-related receptor modulators
EP2084152A2 (en) 2006-11-16 2009-08-05 F. Hoffmann-Roche AG Substituted 4-imidazoles
CN101557810B (en) 2006-12-13 2012-11-21 弗·哈夫曼-拉罗切有限公司 Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
NZ578260A (en) 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
BRPI0807813A2 (en) 2007-02-15 2014-08-05 Hoffmann La Roche 2-AMINO-OXAZOLINS AS TAAR BINDERS
AU2008270445A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (TAARs)
EP2173719A1 (en) 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
KR101167773B1 (en) 2007-08-03 2012-07-24 에프. 호프만-라 로슈 아게 Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
EP2569450A4 (en) * 2010-05-14 2013-12-25 Univ Rochester Compositions and methods for targeting a3g:rna complexes
SI3430010T1 (en) 2016-03-17 2020-10-30 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899426A (en) * 1959-08-11 Synthesis of l
US2516108A (en) * 1950-07-25 Abaleoxyalkylemibazoiilnes
US2899434A (en) * 1959-08-11 Z-phenylamino-l
US2899441A (en) * 1959-08-11 Chjchjoh
US2938038A (en) * 1960-05-24 X-dihydroxyphenylamino
CA625631A (en) * 1961-08-15 Chas. Pfizer And Co. Derivatives of diazacycloalkenes
US1860036A (en) * 1926-09-11 1932-05-24 Gen Aniline Works Inc Pigment dyes
US1912849A (en) * 1928-04-27 1933-06-06 Ig Farbenindustrie Ag Heterocyclic bases of the aminoimidazoline series and process of preparing them
US2824879A (en) * 1956-07-28 1958-02-25 Monsanto Canada Ltd Novel vinyl derivative
US2969372A (en) * 1959-10-01 1961-01-24 Robert A Braun Cycloalkylpyrazolo [3, 4-alpha] inden-4 [1h]-one derivatives
US3048520A (en) * 1960-06-06 1962-08-07 Medical College Of Virginia Fo Antispasmodic
US3063902A (en) * 1961-01-18 1962-11-13 Irwin Neisler & Co Analgesic aralkyl-pyridines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462433A (en) * 1965-10-01 1969-08-19 Boehringer Sohn Ingelheim Derivatives of 2-(2'-halo-anilino)1,3-diazacyclo-pentene-(2)
US3959160A (en) * 1973-05-16 1976-05-25 Wilkinson Sword Limited Aerosol shaving foam compositions
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4262005A (en) * 1978-05-31 1981-04-14 The Boots Company Limited Compounds, compositions and methods for controlling pests
US4287201A (en) * 1980-03-03 1981-09-01 Merck & Co., Inc. Anovulatory method and chicken feed compositions
US4450170A (en) * 1980-07-09 1984-05-22 Beecham Group Limited Treatment of diarrhoea with 2-aminoimidazoline derivatives
US4312879A (en) * 1980-08-14 1982-01-26 Richardson-Merrell Inc. Clonidine and lofexidine as antidiarrheal agents
US4853216A (en) * 1987-04-02 1989-08-01 Bristol-Myers Company Process and composition for the topical application of alpha1 adrenergic agonist for pilomotor effects
US20030114425A1 (en) * 1995-04-20 2003-06-19 Boehringer Ingelheim Pharma Kg Compounds and methods for treating urinary incontinence
US6858594B2 (en) * 1995-04-20 2005-02-22 Boehringer Ingelheim Pharma Gmbh & Co Kg. Compounds and methods for treating urinary incontinence
US20070277873A1 (en) * 2006-06-02 2007-12-06 Emcore Corporation Metamorphic layers in multijunction solar cells
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US8999368B2 (en) 2008-04-18 2015-04-07 Warsaw Orthopedic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20090264490A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US20090263448A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Clonidine Formulation in a Polyorthoester Carrier
US20090263461A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090263450A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US20090263441A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Drug depots having diffreent release profiles for reducing, preventing or treating pain and inflammation
US20090263454A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US20090263460A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Medical devices and methods including polymers having biologically active agents therein
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US20090264491A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20090263459A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and compositions for treating intervertebral disc herniations
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US20090263463A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263321A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Compositions and Methods for Treating Post-Operative Pain Using Clonidine and Bupivacaine
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US9833548B2 (en) 2008-04-18 2017-12-05 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US9775800B2 (en) 2008-04-18 2017-10-03 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US9770438B2 (en) 2008-04-18 2017-09-26 Warsaw Orthopedic, Inc. Clonidine formulation in a polyorthoester carrier
US9763917B2 (en) 2008-04-18 2017-09-19 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US9585872B2 (en) 2008-04-18 2017-03-07 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US9492461B2 (en) 2008-04-18 2016-11-15 Warsaw Orthopedic, Inc. Methods and compositions for treating intervertebral disc herniations
US8420114B2 (en) 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US9387197B2 (en) 2008-04-18 2016-07-12 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090263462A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods for Treating Conditions Such as Dystonia and Post-Stroke Spasticity with Clonidine
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US9351959B2 (en) 2008-04-18 2016-05-31 Warsaw Orthopedic, Inc. Alpha adreneric receptor agonists for treatment of degenerative disc disease
US8889173B2 (en) 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8968767B2 (en) 2008-04-18 2015-03-03 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US9211285B2 (en) 2008-04-18 2015-12-15 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US9265733B2 (en) 2008-04-18 2016-02-23 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100137369A1 (en) * 2008-12-01 2010-06-03 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US10653619B2 (en) 2009-03-23 2020-05-19 Medtronic, Inc. Drug depots for treatment of pain and inflammation
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US20110014259A1 (en) * 2009-07-17 2011-01-20 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110027340A1 (en) * 2009-07-31 2011-02-03 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US9358223B2 (en) 2009-10-26 2016-06-07 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097375A1 (en) * 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site

Also Published As

Publication number Publication date
DK104852C (en) 1966-07-11
NL6800891A (en) 1968-03-25
NL6906535A (en) 1969-07-25
DK107029C (en) 1967-04-17
GB1016514A (en) 1966-01-12
SE301024B (en) 1968-05-20
CH409980A (en) 1966-03-31
US3202660A (en) 1965-08-24
FI42564B (en) 1970-06-01
FI42564C (en) 1970-09-14
MY6700148A (en) 1967-12-31
CY416A (en) 1967-11-14

Similar Documents

Publication Publication Date Title
US3190802A (en) Shaving composition and method of using same
US3426137A (en) Hair growth inhibiting by aminobenzophenones
US5204093A (en) Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
US4759924A (en) Cosmetic sticks
US4617185A (en) Improved deodorant stick
US4034109A (en) Compounds having a physiological cooling effect and compositions containing them
US4020153A (en) Cyclic sulphonamides and sulphinamides having a physiological cooling effect
EP0247766B1 (en) Instant lathering shampoo
US2987446A (en) Cosmetic cream
NZ241382A (en) A shaving product in a self-foaming gel.
US4999183A (en) Shaving compositions
US4613622A (en) Sebosuppressive preparations containing benzyl alcohol derivatives
US3296077A (en) Pilomotor shaving compositions and method of using same
US4833147A (en) Sebosuppressive compositions and method for suppressing sebaceous gland activity
GB1583211A (en) Permanent wawing
US3725525A (en) Hair and nail hardening process
US3296076A (en) Pilomotor shaving compositions and method of using same
NZ241952A (en) Aerosol instant foaming shave cream containing an alkanolamine soap, a non-ionic surfactant, and a foam stabilizer
EP0129197B1 (en) Hair growth promoting composition
EP0170269A2 (en) Medicated cosmetic compositions
US4917884A (en) Shaving compositions
US7179454B2 (en) Personal care composition for shaving
US4668705A (en) Sebosuppressive preparations containing alkoxyaryl alkanols
GB1051461A (en) Dermatologic composition
US4980159A (en) Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects